Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amarin Corp. PLC

www.amarincorp.com

Latest From Amarin Corp. PLC

Amarin Seeks EU Fast-Track For Potential Cardiovascular Blockbuster

Amarin’s cardiovascular risk reducing drug, Vascepa, is among four new products being considered for accelerated assessment by the European Medicines Agency.

Drug Review Europe

Amarin CEO Thero On Gearing Up For Success Ahead Of The Big Vascepa Ad Comm

"We're planning for success," John Thero told Scrip in an interview, where he talked about the upcoming US advisory committee meeting for Vascepa, commercial expansion plans and deflected questions about a big pharma buyout.

Launches Drug Review

Vascepa Advisory Committee Is Latest Outpost In Product's Remarkable Regulatory Journey

The last time representatives from Amarin and US FDA formally met in public, it was in court.

Advisory Committees Cardiovascular

Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits 'Too Long'

As Amarin expects jump in Vascepa sales from potential label expansion allowing larger patient group, John Thero notes competitors fail to show broader cardiovascular risk reduction, but consumers still hear omega-3 supplements "might work."

Dietary Supplements Regulation
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register